Tissue Factor Pathway Inhibitor Attenuates the Progression of Malignant Pleural Mesothelioma in Nude Mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 2, 2012, Pages 173-179

  Williams, LaTerrica ^a   Tucker, Torry A ^a   Koenig, Kathy ^a   Allen, Timothy ^a   Rao, L Vijaya Mohan ^a   Pendurthi, Usha ^a   Idell, Steven ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

Invasion; Malignant pleural mesothelioma; Proliferation; Tissue factor pathway inhibitor; Tumorigenesis

Indexed keywords

BLOOD CLOTTING FACTOR 10; COLLAGEN; FIBRIN; PROCOAGULANT; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; EX VIVO STUDY; FIBRIN DEPOSITION; GENE TARGETING; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOUSE; NONHUMAN; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VOLUME;

ANIMALS; DISEASE PROGRESSION; LIPOPROTEINS; MESOTHELIOMA; MICE; MICE, NUDE; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

MUS MUSCULUS;

EID: 84856647361     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0276OC     Document Type: Article

References (21)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603. (Pubitemid 41434638)
2. Nasreen N, Mohammed KA, Mubarak KK, Baz MA, Akindipe OA, Fernandez-Bussy S, Antony VB. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am J Physiol Lung Cell Mol Physiol 2009;297:L115-L124.
3. Idell S, Pueblitz S, Emri S, Gungen Y, Gray L, Kumar A, Holiday D, Koenig KB, Johnson AR. Regulation of fibrin deposition by malignant mesothelioma. Am J Pathol 1995;147:1318-1329.
4. Tucker TA, Dean C, Komissarov A, Koenig K, Mazar A, Allen T, Pendurthi U, Idell S. The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells. Am J Respir Cell Mol Biol 2010;42:685-696.
5. Dvorak HF. Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659. (Pubitemid 17052899)
6. Bluff JE, Brown NJ, Reed MW, Staton CA. Tissue factor, angiogenesis and tumour progression. Breast Cancer Res 2008;10:204.
7. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992;70:1194-1201.
8. Schaffner F, Ruf W. Tissue factor and protease-activated receptor signaling in cancer. Semin Thromb Hemost 2008;34:147-153.
9. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahamed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10:502-509. (Pubitemid 38667909)
10. Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001;73:145-150. (Pubitemid 33758853)
11. Amirkhosravi A, Meyer T, Amaya M, Davila M, Mousa SA, Robson T, Francis JL. The role of tissue factor pathway inhibitor in tumor growth and metastasis. Semin Thromb Hemost 2007;33:643-652. (Pubitemid 350157007)
12. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV. Tissue factor-Factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004;103:3029-3037. (Pubitemid 38451676)
13. Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS. Tissue factor/Factor VIIA inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003;63:2997-3000. (Pubitemid 36667175)
14. Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002;87:930-936. (Pubitemid 34624872)
15. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209.
16. Rao LV, Pendurthi UR. Sharing tissue factor: a winning strategy in tumorigenesis. Arterioscler Thromb Vasc Biol 2008;28:1885-1886.
17. Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression and angiogenesis. Thromb Res 2010;125:S36-S38.
18. Bajaj MS, Pendurthi U, Koenig K, Pueblitz S, Idell S. Tissue factor pathway inhibitor expression by human pleural mesothelial and mesothelioma cells. Eur Respir J 2000;15:1069-1078. (Pubitemid 30399277)
19. Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238-247. (Pubitemid 37430063)
20. de Jonge E, Dekkers PE, Creasey AA, Hack CE, Paulson SK, Karim A, Kesecioglu J, Levi M, van Deventer SJ, van Der Poll T. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000;95:1124-1129. (Pubitemid 30099814)
21. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011;183:1561-1568.